 The overall aim of this study was to evaluate whether iodine-131 radiolabeled monoclonal antibody ( mAb) targeting programmed death-ligand 1 ( PD-L1) can be used for imaging of PD-L1 expression noninvasively in vivo and playing synergistic effect combined with immunotherapy. Anti-PD-L1 mAb was radiolabeled with iodine-131 (